Total raised
—
Last: Seed 2019-11
Stage
Series A
Founded
2020
Headcount
6
HQ
Haifa
Sector
Health Tech & Life Sciences
About
Canopy is a pre-clinical stage biotech developing a new class of biologics that will allow the elimination of antigen-specific immunity, providing non-immunosuppressive, potentially curing treatments to many dozens of autoimmune, allergic, and other antibody-mediated conditions using its proprietary Reverse-Immunization platform.
Funding history · 1 round · — total
2019-11
Seed
Undisclosed
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Canopy Immuno-Therapeutics' primary focus?
- Canopy Immuno-Therapeutics is a pre-clinical stage biotech company focused on developing a new class of biologics to eliminate antigen-specific immunity. This aims to provide non-immunosuppressive treatments for autoimmune, allergic, and other antibody-mediated conditions using its proprietary Reverse-Immunization platform.
- When was Canopy Immuno-Therapeutics founded?
- Canopy Immuno-Therapeutics was founded in January 2020.
- What is the current employee count for Canopy Immuno-Therapeutics?
- Canopy Immuno-Therapeutics currently has 6 employees.
- Which investor participated in Canopy Immuno-Therapeutics' seed round?
- TLV Partners participated in Canopy Immuno-Therapeutics' Seed funding round in November 2019.
- What is the current funding stage of Canopy Immuno-Therapeutics?
- Canopy Immuno-Therapeutics is currently in the Series A funding stage.
- Where is Canopy Immuno-Therapeutics headquartered?
- Canopy Immuno-Therapeutics is headquartered in Haifa, Israel.
- What is the name of Canopy Immuno-Therapeutics' proprietary platform?
- Canopy Immuno-Therapeutics utilizes a proprietary platform called Reverse-Immunization.
- Has Canopy Immuno-Therapeutics been mentioned in any notable publications?
- Yes, in November 2020, research related to SARS-CoV-2 serology assays was published in The Lancet, mentioning a multi-center nationwide comparison.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Platforms & InterfacesSoftwareArtificial Intelligence
Target customers
Healthcare & Life SciencesLife SciencesBiotechnology
Business model
B2B
Highlights
Verified
Tags
biotechnologyinflammatory-diseasesallergytreatmentsartificial-intelligencesoftware-platformlife-sciencesimmunologyimmuno-theraphydrug-developmentimmunotherapy